HK1210962A1 - Methods for treatment of atherosclerosis - Google Patents
Methods for treatment of atherosclerosis Download PDFInfo
- Publication number
- HK1210962A1 HK1210962A1 HK15111866.1A HK15111866A HK1210962A1 HK 1210962 A1 HK1210962 A1 HK 1210962A1 HK 15111866 A HK15111866 A HK 15111866A HK 1210962 A1 HK1210962 A1 HK 1210962A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- atherosclerosis
- treatment
- subject
- subjects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261678992P | 2012-08-02 | 2012-08-02 | |
| US201261678992P | 2012-08-02 | ||
| US201261695850P | 2012-08-31 | 2012-08-31 | |
| US201261695807P | 2012-08-31 | 2012-08-31 | |
| US201261695850P | 2012-08-31 | ||
| US201261695807P | 2012-08-31 | ||
| PCT/US2013/053008 WO2014022552A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1210962A1 true HK1210962A1 (en) | 2016-05-13 |
Family
ID=50028503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15111866.1A HK1210962A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
| HK15111769.9A HK1210953A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15111769.9A HK1210953A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10188693B2 (cg-RX-API-DMAC7.html) |
| EP (6) | EP3662921A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2015529655A (cg-RX-API-DMAC7.html) |
| CN (3) | CN110090304A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2013296494B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2880643A1 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1210962A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2014022551A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107312066A (zh) * | 2011-12-09 | 2017-11-03 | 康德生物医疗技术公司 | 芳香族阳离子肽及其用途 |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| JP2015529655A (ja) * | 2012-08-02 | 2015-10-08 | ステルス ペプチドズ インターナショナル インコーポレイテッド | アテローム性硬化症の処置方法 |
| CN110193077A (zh) * | 2012-10-22 | 2019-09-03 | 康德生物医疗技术公司 | 降低与心脏衰竭相关的风险和与其相关的因素的方法 |
| WO2015183970A1 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including flavonoid and uses thereof |
| WO2015183984A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including tocopherol and uses thereof |
| WO2015183985A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including naphthoquinones and uses thereof |
| RU2623876C2 (ru) * | 2014-11-10 | 2017-06-29 | Александр Владимирович Диковский | Фармацевтическая композиция для лечения гиперлипидемии |
| WO2016190852A1 (en) * | 2015-05-26 | 2016-12-01 | Stealth Peptides International, Inc. | Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof |
| US20180318381A1 (en) * | 2015-10-23 | 2018-11-08 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Methods of Treatment of Rhabdomyolysis |
| US11355245B2 (en) * | 2016-05-03 | 2022-06-07 | International Business Machines Corporation | Identifying and ranking risk factors using trained predictive models |
| ES2871783T3 (es) * | 2016-09-20 | 2021-11-02 | Univ Aarhus | Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas |
| CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
| IL322723A (en) | 2017-04-05 | 2025-10-01 | Stealth Biotherapeutics Inc | Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| GB202005439D0 (en) | 2020-04-14 | 2020-05-27 | Aurigen Medical Ltd | A device for occlusion of a left a trial appendage of a heart |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4489710A (en) | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| CA2455336A1 (en) | 2001-08-10 | 2003-02-20 | Novartis Ag | Peptides that bind to atherosclerotic lesions |
| PT1599216E (pt) * | 2003-02-04 | 2013-12-17 | Cornell Res Foundation Inc | Métodos de prevenção da transição de permeabilidade mitocondrial |
| DK2604285T3 (en) * | 2003-05-01 | 2014-12-01 | Cornell Res Foundation Inc | Method and carrier complex for delivering molecules to cells |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| EP3725324A1 (en) * | 2005-09-16 | 2020-10-21 | Cornell Research Foundation, Inc. | Aromatic-cationic peptide for use in a method for reducing cd36 expression |
| JP2009525281A (ja) * | 2006-01-30 | 2009-07-09 | イスラエル ベン デビッド ブライソン、 | 心臓血管系疾患、脳血管系疾患および他の血管系疾患の患者を治療するための組成物ならびに方法 |
| JP4881385B2 (ja) | 2006-08-30 | 2012-02-22 | 国立大学法人九州大学 | スタチン封入ナノ粒子含有医薬組成物 |
| WO2009092071A2 (en) | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof |
| DK2252312T3 (da) * | 2008-02-07 | 2014-06-16 | Univ Cornell | Fremgangsmåder til forebyggelse eller behandling af insulinresistens |
| JP5909182B2 (ja) * | 2009-08-12 | 2016-04-26 | コーネル ユニヴァーシティー | 代謝性症候群を予防し又は治療するための方法 |
| EP3338788A1 (en) * | 2009-08-24 | 2018-06-27 | Stealth Peptides International, Inc. | Methods and copositions for preventing or treating opthalmic conditions |
| US20130040901A1 (en) * | 2010-02-26 | 2013-02-14 | University Of Florida Research Foundation Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP3040080A1 (en) * | 2010-03-15 | 2016-07-06 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| MX2013007168A (es) | 2010-12-22 | 2013-11-04 | Genentech Inc | Anticuerpo anti-pcsk9 y metodos de uso. |
| JP2015529655A (ja) * | 2012-08-02 | 2015-10-08 | ステルス ペプチドズ インターナショナル インコーポレイテッド | アテローム性硬化症の処置方法 |
-
2013
- 2013-07-31 JP JP2015525554A patent/JP2015529655A/ja active Pending
- 2013-07-31 US US14/418,827 patent/US10188693B2/en active Active
- 2013-07-31 EP EP19209275.7A patent/EP3662921A1/en not_active Withdrawn
- 2013-07-31 CA CA2880643A patent/CA2880643A1/en not_active Abandoned
- 2013-07-31 JP JP2015525555A patent/JP2015524439A/ja active Pending
- 2013-07-31 AU AU2013296494A patent/AU2013296494B2/en active Active
- 2013-07-31 WO PCT/US2013/053007 patent/WO2014022551A1/en not_active Ceased
- 2013-07-31 US US14/418,809 patent/US10201585B2/en active Active
- 2013-07-31 CA CA2880648A patent/CA2880648A1/en not_active Abandoned
- 2013-07-31 EP EP18198495.6A patent/EP3485897A1/en not_active Withdrawn
- 2013-07-31 CN CN201910002871.XA patent/CN110090304A/zh active Pending
- 2013-07-31 EP EP16174236.6A patent/EP3132800A1/en not_active Withdrawn
- 2013-07-31 WO PCT/US2013/053008 patent/WO2014022552A1/en not_active Ceased
- 2013-07-31 HK HK15111866.1A patent/HK1210962A1/xx unknown
- 2013-07-31 EP EP13825389.3A patent/EP2879689A4/en not_active Withdrawn
- 2013-07-31 CN CN201380049785.5A patent/CN104661670A/zh active Pending
- 2013-07-31 AU AU2013296493A patent/AU2013296493B2/en active Active
- 2013-07-31 HK HK15111769.9A patent/HK1210953A1/xx unknown
- 2013-07-31 EP EP17186931.6A patent/EP3300740A1/en not_active Withdrawn
- 2013-07-31 EP EP13824883.6A patent/EP2879688A4/en not_active Withdrawn
- 2013-07-31 CN CN201380049762.4A patent/CN104768564A/zh active Pending
-
2017
- 2017-10-04 JP JP2017194137A patent/JP2018016637A/ja active Pending
- 2017-10-06 JP JP2017195835A patent/JP2018012726A/ja active Pending
- 2017-12-20 US US15/848,712 patent/US20180339012A1/en not_active Abandoned
- 2017-12-20 US US15/848,198 patent/US20180344797A1/en not_active Abandoned
-
2018
- 2018-03-23 AU AU2018202068A patent/AU2018202068A1/en not_active Abandoned
- 2018-03-27 AU AU2018202197A patent/AU2018202197A1/en not_active Abandoned
-
2019
- 2019-02-08 US US16/271,185 patent/US20200000870A1/en not_active Abandoned
- 2019-03-08 JP JP2019042213A patent/JP2019108389A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1210962A1 (en) | Methods for treatment of atherosclerosis | |
| PH12021550756A1 (en) | Compositions and methods for treating and/or preventing cardiovascular disease | |
| AU2018253546A1 (en) | Aromatic-cationic peptides and methods for using same | |
| EP2528934A4 (en) | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF | |
| HK1210599A1 (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| WO2014062720A3 (en) | Methods of treating cancer | |
| WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
| WO2011007183A3 (en) | Skin care composition for the treatment of acne vulgaris | |
| WO2010087964A3 (en) | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof | |
| HK1214521A1 (zh) | 用於治療蛋白質病的組合物和方法 | |
| PT2848097T (pt) | Dispositivo para o tratamento de plasma de superfícies humanas, animais ou de plantas, em particular da pele ou de áreas de membrana mucosa | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| WO2011121576A3 (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| WO2013117744A3 (en) | Methods of treating fibrosis | |
| WO2013114394A8 (en) | A polyherbal composition for skin care | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| WO2014085749A3 (en) | Antibodies against clostridium difficile | |
| WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| HK1215391A1 (zh) | 使用胎盘细胞外基质治疗口腔病变 | |
| WO2011113785A3 (en) | A cosmetic composition for rejuvenating skin appearance | |
| PH12015501131A1 (en) | Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states | |
| WO2013192238A3 (en) | Compositions and methods for treatment of diabetes | |
| WO2014031982A3 (en) | Methods and compositions for treating pain |